Technical Analysis for VCNX - Vaccinex, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | -6.13% | |
| Crossed Above 50 DMA | Bullish | -6.13% | |
| Wide Bands | Range Expansion | -6.13% | |
| 20 DMA Resistance | Bearish | 6.82% | |
| Wide Bands | Range Expansion | 6.82% | |
| Gapped Up | Strength | 6.82% | |
| 20 DMA Resistance | Bearish | 11.97% | |
| Inside Day | Range Contraction | 11.97% | |
| Wide Bands | Range Expansion | 11.97% | |
| Bearish Engulfing | Bearish | 10.20% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 1 hour ago |
| Down 5% | about 1 hour ago |
| Down 3% | about 1 hour ago |
| Down 2 % | about 1 hour ago |
Get a Trading Assistant
- Earnings date: 11/11/2024
Vaccinex, Inc. Description
Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Immunology Immune System Antibodies Clinical Development Monoclonal Antibodies Antibody Non Small Cell Lung Cancer Melanoma Neurodegenerative Diseases Small Cell Lung Cancer Multiple Sclerosis Sarcoma Autoimmune Disorders Degenerative Disease Immune Disorders NSCLC Treatment Of Non Small Cell Lung Cancer Human Monoclonal Antibodies Osteosarcoma Treatment Of Multiple Sclerosis Seth Lederman Vaccinia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.02 |
| 52 Week Low | 1.39 |
| Average Volume | 115,578 |
| 200-Day Moving Average | 5.81 |
| 50-Day Moving Average | 3.37 |
| 20-Day Moving Average | 3.36 |
| 10-Day Moving Average | 3.33 |
| Average True Range | 0.47 |
| RSI (14) | 57.08 |
| ADX | 20.37 |
| +DI | 27.46 |
| -DI | 16.29 |
| Chandelier Exit (Long, 3 ATRs) | 3.40 |
| Chandelier Exit (Short, 3 ATRs) | 4.05 |
| Upper Bollinger Bands | 3.94 |
| Lower Bollinger Band | 2.77 |
| Percent B (%b) | 0.8 |
| BandWidth | 34.87 |
| MACD Line | 0.04 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0448 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.37 | ||||
| Resistance 3 (R3) | 4.30 | 4.01 | 4.26 | ||
| Resistance 2 (R2) | 4.01 | 3.84 | 4.05 | 4.22 | |
| Resistance 1 (R1) | 3.86 | 3.74 | 3.94 | 3.93 | 4.19 |
| Pivot Point | 3.57 | 3.57 | 3.61 | 3.61 | 3.57 |
| Support 1 (S1) | 3.42 | 3.40 | 3.50 | 3.49 | 3.23 |
| Support 2 (S2) | 3.13 | 3.30 | 3.17 | 3.20 | |
| Support 3 (S3) | 2.98 | 3.13 | 3.16 | ||
| Support 4 (S4) | 3.05 |
